Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
dianicline · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| dianicline | DRUG | - |
Inclusion Criteria: * Outpatients over the legal age smoking at least 10 cigarettes per day for at least 2 months Exclusion Criteria: * Insufficient level of motivation * Another participant in the household * Patients with current psychotic disorder or major depressive disorder The investigator...
Dianicline is an investigational small molecule developed by Sanofi as an aid to smoking cessation. It was studied in a Phase 3 clinical trial in adults aged 18 years and older who wanted to stop smoking. It is not described as an approved therapy and remains a clinical-stage candidate.
Dianicline was developed as a smoking cessation aid, intended to help adults quit smoking. Its Phase 3 trial, NCT00356967, evaluated efficacy and safety versus placebo in 602 participants across Belgium, Denmark, France, Norway, Spain, and Sweden. The study enrolled both men and women aged 18 years and older.
Dianicline targets the nicotinic acetylcholine receptor subunits CHRNB2 and CHRNA4. It acts as a partial agonist at these receptors, a mechanism intended to ease nicotine craving and withdrawal symptoms during smoking cessation. This receptor activity is the basis for its investigation as a smoking cessation aid.
Dianicline is developed by Sanofi, which trades under the ticker SNY. Sanofi sponsored the Phase 3 smoking cessation trial of dianicline. The compound is a small molecule and is identified in ChEMBL under the ID CHEMBL187927.
Dianicline reached Phase 3 clinical development. Its single registered trial, NCT00356967, was a completed Phase 3 study of efficacy and safety versus placebo as an aid to smoking cessation. Dianicline is an investigational agent and is not described as an approved product.
Dianicline has been studied in one registered clinical trial, NCT00356967, titled Efficacy and Safety of Dianicline Versus Placebo as an Aid to Smoking Cessation. That Phase 3 trial is completed, was randomized and double blind, and enrolled 602 participants across six European countries.